Can	O
LDL	B:C0023824
cholesterol	I:C0023824
be	O
too	O
low	O
?	O

Following	O
the	O
continuous	O
accumulation	B:C4055506
of	O
evidence	O
supporting	O
the	O
beneficial	O
role	O
of	O
reducing	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
(	I:C0202117
LDL	I:C0202117
-	I:C0202117
C	I:C0202117
)	I:C0202117
levels	I:C0202117
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
and	O
its	O
complications	O
,	O
therapeutic	O
possibilities	O
now	O
exist	O
to	O
lower	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
to	O
very	O
low	O
levels	O
,	O
similar	O
to	O
or	O
even	O
lower	O
than	O
those	O
seen	O
in	O
newborns	O
and	O
nonhuman	O
species	I:C0003062
.	O

Following	O
the	O
continuous	O
accumulation	O
of	O
evidence	O
supporting	O
the	O
beneficial	O
role	O
of	O
reducing	O
low	B:C0202117
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
(	I:C0202117
LDL	I:C0202117
-	I:C0202117
C	I:C0202117
)	I:C0202117
levels	I:C0202117
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
and	O
its	O
complications	O
,	O
therapeutic	O
possibilities	O
now	O
exist	O
to	O
lower	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
to	O
very	O
low	O
levels	O
,	O
similar	O
to	O
or	O
even	O
lower	O
than	O
those	O
seen	O
in	O
newborns	O
and	O
nonhuman	O
species	I:C0003062
.	O

Following	O
the	O
continuous	O
accumulation	O
of	O
evidence	O
supporting	O
the	O
beneficial	O
role	O
of	O
reducing	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
(	I:C0202117
LDL	I:C0202117
-	I:C0202117
C	I:C0202117
)	I:C0202117
levels	I:C0202117
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerotic	B:C0004153
cardiovascular	I:C0004153
disease	I:C0004153
and	O
its	O
complications	O
,	O
therapeutic	O
possibilities	O
now	O
exist	O
to	O
lower	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
to	O
very	O
low	O
levels	O
,	O
similar	O
to	O
or	O
even	O
lower	O
than	O
those	O
seen	O
in	O
newborns	O
and	O
nonhuman	O
species	I:C0003062
.	O

Following	O
the	O
continuous	O
accumulation	O
of	O
evidence	O
supporting	O
the	O
beneficial	O
role	O
of	O
reducing	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
(	I:C0202117
LDL	I:C0202117
-	I:C0202117
C	I:C0202117
)	I:C0202117
levels	I:C0202117
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
and	O
its	O
complications	B:C0009566
,	O
therapeutic	O
possibilities	O
now	O
exist	O
to	O
lower	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
to	O
very	O
low	O
levels	O
,	O
similar	O
to	O
or	O
even	O
lower	O
than	O
those	O
seen	O
in	O
newborns	O
and	O
nonhuman	O
species	I:C0003062
.	O

Following	O
the	O
continuous	O
accumulation	O
of	O
evidence	O
supporting	O
the	O
beneficial	O
role	O
of	O
reducing	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
(	I:C0202117
LDL	I:C0202117
-	I:C0202117
C	I:C0202117
)	I:C0202117
levels	I:C0202117
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
and	O
its	O
complications	O
,	O
therapeutic	O
possibilities	O
now	O
exist	O
to	O
lower	O
low	B:C0202117
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
to	O
very	O
low	O
levels	O
,	O
similar	O
to	O
or	O
even	O
lower	O
than	O
those	O
seen	O
in	O
newborns	O
and	O
nonhuman	O
species	I:C0003062
.	O

Following	O
the	O
continuous	O
accumulation	O
of	O
evidence	O
supporting	O
the	O
beneficial	O
role	O
of	O
reducing	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
(	I:C0202117
LDL	I:C0202117
-	I:C0202117
C	I:C0202117
)	I:C0202117
levels	I:C0202117
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerotic	O
cardiovascular	I:C0004153
disease	I:C0004153
and	O
its	O
complications	O
,	O
therapeutic	O
possibilities	O
now	O
exist	O
to	O
lower	O
low	O
-	I:C0202117
density	I:C0202117
lipoprotein	I:C0202117
cholesterol	I:C0202117
to	O
very	O
low	O
levels	O
,	O
similar	O
to	O
or	O
even	O
lower	O
than	O
those	O
seen	O
in	O
newborns	O
and	O
nonhuman	B:C0003062
species	I:C0003062
.	O

In	O
addition	O
to	O
the	O
important	O
task	O
of	O
evaluating	B:C0220825
potential	O
side	O
effects	I:C0879626
of	O
such	O
treatments	O
,	O
the	O
question	O
arises	O
whether	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
per	O
se	O
may	O
provoke	O
adverse	O
effects	I:C0879626
in	O
humans	O
.	O

In	O
addition	O
to	O
the	O
important	O
task	O
of	O
evaluating	O
potential	O
side	B:C0879626
effects	I:C0879626
of	O
such	O
treatments	O
,	O
the	O
question	O
arises	O
whether	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
per	O
se	O
may	O
provoke	O
adverse	O
effects	I:C0879626
in	O
humans	O
.	O

In	O
addition	O
to	O
the	O
important	O
task	O
of	O
evaluating	O
potential	O
side	O
effects	I:C0879626
of	O
such	O
treatments	O
,	O
the	O
question	O
arises	O
whether	O
extremely	O
low	O
LDL	B:C0202117
-	I:C0202117
C	I:C0202117
levels	I:C0202117
per	O
se	O
may	O
provoke	O
adverse	O
effects	I:C0879626
in	O
humans	O
.	O

In	O
addition	O
to	O
the	O
important	O
task	O
of	O
evaluating	O
potential	O
side	O
effects	I:C0879626
of	O
such	O
treatments	O
,	O
the	O
question	O
arises	O
whether	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
per	O
se	O
may	O
provoke	O
adverse	B:C0879626
effects	I:C0879626
in	O
humans	O
.	O

In	O
addition	O
to	O
the	O
important	O
task	O
of	O
evaluating	O
potential	O
side	O
effects	I:C0879626
of	O
such	O
treatments	O
,	O
the	O
question	O
arises	O
whether	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
per	O
se	O
may	O
provoke	O
adverse	O
effects	I:C0879626
in	O
humans	B:C0086418
.	O

In	O
this	O
review	B:C0282443
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	O
cellular	O
and	O
organ	O
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	I:C0019247
of	O
lipid	O
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	O
trials	I:C0008976
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	B:C0008972
of	O
human	O
cellular	O
and	O
organ	O
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	I:C0019247
of	O
lipid	O
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	O
trials	I:C0008976
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	B:C0086418
cellular	O
and	O
organ	O
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	I:C0019247
of	O
lipid	O
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	O
trials	I:C0008976
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	O
cellular	B:C0007634
and	O
organ	O
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	I:C0019247
of	O
lipid	O
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	O
trials	I:C0008976
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	O
cellular	O
and	O
organ	B:C0031843
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	I:C0019247
of	O
lipid	O
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	O
trials	I:C0008976
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	O
cellular	O
and	O
organ	O
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	B:C0019247
diseases	I:C0019247
of	O
lipid	O
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	O
trials	I:C0008976
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	O
cellular	O
and	O
organ	O
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	I:C0019247
of	O
lipid	B:C0598783
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	O
trials	I:C0008976
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	O
cellular	O
and	O
organ	O
physiology	I:C0031843
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	I:C0019247
of	O
lipid	O
metabolism	I:C0598783
,	O
and	O
experience	O
from	O
clinical	B:C0008976
trials	I:C0008976
.	O

Specifically	O
,	O
we	O
emphasize	O
the	O
importance	O
of	O
the	O
robustness	O
of	O
the	O
regulatory	O
systems	O
that	O
maintain	O
balanced	B:C0014653
fluxes	O
and	O
levels	O
of	I:C0428466
cholesterol	I:C0428466
at	O
both	O
cellular	O
and	O
organismal	O
levels	O
.	O

Specifically	O
,	O
we	O
emphasize	O
the	O
importance	O
of	O
the	O
robustness	O
of	O
the	O
regulatory	O
systems	O
that	O
maintain	O
balanced	O
fluxes	O
and	O
levels	B:C0428466
of	I:C0428466
cholesterol	I:C0428466
at	O
both	O
cellular	O
and	O
organismal	O
levels	O
.	O

Specifically	O
,	O
we	O
emphasize	O
the	O
importance	O
of	O
the	O
robustness	O
of	O
the	O
regulatory	O
systems	O
that	O
maintain	O
balanced	O
fluxes	O
and	O
levels	O
of	I:C0428466
cholesterol	I:C0428466
at	O
both	O
cellular	B:C0007634
and	O
organismal	O
levels	O
.	O

Even	O
at	O
extremely	O
low	O
LDL	B:C0202117
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	B:C0301818
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	B:C1157403
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	B:C0033085
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	B:C0150312
of	O
a	O
cholesterol	O
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	B:C0008377
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood	B:C0005854
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	B:C0524828
cells	I:C0524828
in	O
the	O
central	O
nervous	I:C3714787
system	I:C3714787
.	O

Even	O
at	O
extremely	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	I:C0301818
and	O
bile	O
acid	I:C1157403
production	I:C1157403
are	O
preserved	O
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood	O
-	I:C0005854
brain	I:C0005854
barrier	I:C0005854
protects	O
cells	I:C0524828
in	O
the	O
central	B:C3714787
nervous	I:C3714787
system	I:C3714787
.	O

Apparent	O
relationships	O
sometimes	O
reported	O
between	O
less	O
pronounced	O
low	O
LDL	B:C0202117
-	I:C0202117
C	I:C0202117
levels	I:C0202117
and	O
disease	O
states	I:C3887610
such	O
as	O
cancer	O
,	O
depression	O
,	O
infectious	O
disease	I:C0009450
and	O
others	O
can	O
generally	O
be	O
explained	O
as	O
secondary	O
phenomena	O
.	O

Apparent	O
relationships	O
sometimes	O
reported	O
between	O
less	O
pronounced	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
and	O
disease	B:C3887610
states	I:C3887610
such	O
as	O
cancer	O
,	O
depression	O
,	O
infectious	O
disease	I:C0009450
and	O
others	O
can	O
generally	O
be	O
explained	O
as	O
secondary	O
phenomena	O
.	O

Apparent	O
relationships	O
sometimes	O
reported	O
between	O
less	O
pronounced	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
and	O
disease	O
states	I:C3887610
such	O
as	O
cancer	B:C0006826
,	O
depression	O
,	O
infectious	O
disease	I:C0009450
and	O
others	O
can	O
generally	O
be	O
explained	O
as	O
secondary	O
phenomena	O
.	O

Apparent	O
relationships	O
sometimes	O
reported	O
between	O
less	O
pronounced	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
and	O
disease	O
states	I:C3887610
such	O
as	O
cancer	O
,	O
depression	B:C0011581
,	O
infectious	O
disease	I:C0009450
and	O
others	O
can	O
generally	O
be	O
explained	O
as	O
secondary	O
phenomena	O
.	O

Apparent	O
relationships	O
sometimes	O
reported	O
between	O
less	O
pronounced	O
low	O
LDL	O
-	I:C0202117
C	I:C0202117
levels	I:C0202117
and	O
disease	O
states	I:C3887610
such	O
as	O
cancer	O
,	O
depression	O
,	O
infectious	B:C0009450
disease	I:C0009450
and	O
others	O
can	O
generally	O
be	O
explained	O
as	O
secondary	O
phenomena	O
.	O

Drug	B:C0041755
-	I:C0041755
related	I:C0041755
side	I:C0041755
effects	I:C0041755
including	O
an	O
increased	O
propensity	O
for	O
development	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
occur	O
during	O
statin	O
treatment	O
,	O
whilst	O
further	O
evaluation	O
of	O
more	O
potent	O
LDL	O
-	O
lowering	O
treatments	O
such	O
as	O
PCSK9	O
inhibitors	I:C4051516
is	O
needed	O
.	O

Drug	O
-	I:C0041755
related	I:C0041755
side	I:C0041755
effects	I:C0041755
including	O
an	O
increased	O
propensity	O
for	O
development	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
occur	O
during	O
statin	O
treatment	O
,	O
whilst	O
further	O
evaluation	O
of	O
more	O
potent	O
LDL	O
-	O
lowering	O
treatments	O
such	O
as	O
PCSK9	O
inhibitors	I:C4051516
is	O
needed	O
.	O

Drug	O
-	I:C0041755
related	I:C0041755
side	I:C0041755
effects	I:C0041755
including	O
an	O
increased	O
propensity	O
for	O
development	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
occur	O
during	O
statin	O
treatment	O
,	O
whilst	O
further	O
evaluation	B:C0220825
of	O
more	O
potent	O
LDL	O
-	O
lowering	O
treatments	O
such	O
as	O
PCSK9	O
inhibitors	I:C4051516
is	O
needed	O
.	O

Drug	O
-	I:C0041755
related	I:C0041755
side	I:C0041755
effects	I:C0041755
including	O
an	O
increased	O
propensity	O
for	O
development	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
occur	O
during	O
statin	O
treatment	O
,	O
whilst	O
further	O
evaluation	O
of	O
more	O
potent	O
LDL	B:C0023824
-	O
lowering	O
treatments	O
such	O
as	O
PCSK9	O
inhibitors	I:C4051516
is	O
needed	O
.	O

Drug	O
-	I:C0041755
related	I:C0041755
side	I:C0041755
effects	I:C0041755
including	O
an	O
increased	O
propensity	O
for	O
development	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
occur	O
during	O
statin	O
treatment	O
,	O
whilst	O
further	O
evaluation	O
of	O
more	O
potent	O
LDL	O
-	O
lowering	O
treatments	O
such	O
as	O
PCSK9	B:C4051516
inhibitors	I:C4051516
is	O
needed	O
.	O

Experience	O
from	O
the	O
recently	O
reported	O
and	O
ongoing	O
large	O
event	O
-	O
driven	O
trials	B:C0008976
are	O
of	O
great	O
interest	O
,	O
and	O
further	O
evaluation	O
including	O
careful	O
analysis	O
of	O
cognitive	O
functions	O
will	O
be	O
important	O
.	O

Experience	O
from	O
the	O
recently	O
reported	O
and	O
ongoing	O
large	O
event	O
-	O
driven	O
trials	O
are	O
of	O
great	O
interest	O
,	O
and	O
further	O
evaluation	B:C0220825
including	O
careful	O
analysis	O
of	O
cognitive	O
functions	O
will	O
be	O
important	O
.	O

Experience	O
from	O
the	O
recently	O
reported	O
and	O
ongoing	O
large	O
event	O
-	O
driven	O
trials	O
are	O
of	O
great	O
interest	O
,	O
and	O
further	O
evaluation	O
including	O
careful	O
analysis	B:C0936012
of	O
cognitive	O
functions	O
will	O
be	O
important	O
.	O

